title: [Donor peripheral stem cells infusion for the treatment of failure of platelet recovery after allogeneic hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To study the safety and effect of G-CSF mobilized donor hematopoietic stem cells infusion (GPBSCI) as the therapy for the failure of platelet recovery after allogeneic hematopoietic stem cell transplantation.
  
  
  METHODS
  The clinical data of 15 patients with acute or chronic leukemia undergoing GPBSCI 16 times, 9 males and 6 females, aged 33 (14 approximately 48), were retrospectively analyzed.
  
  
  RESULTS
  The median number of mononuclear cells (MNC) from bone marrow was (4.21 +/- 1.91) x 10(8)/kg (1.50 x 10(8)/kg approximately 7.46 x 10(8)/kg). The median number of MNCs from peripheral blood was (3.27 +/- 1.40) x 10(8)/kg (1.13 x 10(8)/kg approximately 5.90 x 10(8)/kg). The median CD34+ count was (2.13 +/- 1.69) x 10(6)/kg (0.24 x 10(6)/kg approximately 5.67 x 10(6)/kg). All the patients had achieved white cell engraftment. 8 patients with primary failure of platelet recovery and 7 patients with secondary failure of platelet recovery received donor peripheral stem cells infusion. The median day of infusion was +113 days (43 approximately 384 days). The median number of infused mononuclear cells was (3.09 +/- 1.54) x 10(8)/kg (1.35 approximately 5.99) x 10(8)/kg. Only 1 patient had transfusion related GVHD. Clinical efficacy was seen in 9 patients (56.3%). The efficacy of infusion within 100 day after transplantation was 87.50%, significantly higher than that conducted 100 days after the transplantation (25.00%, P = 0.012).
  
  
  CONCLUSIONS
  With minimal side effect, GPBSCI may be an effective strategy for the therapy of failure of platelet recovery.
authors.affiliation: Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Yao
authors.initials: Y
authors.lastname: Chen
authors.forename: Lan-ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Dai-hong
authors.initials: DH
authors.lastname: Liu
authors.forename: Yun-hong
authors.initials: YH
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Han
authors.forename: Hong-xia
authors.initials: HX
authors.lastname: Shi
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Zhang
authors.forename: Jing-zhi
authors.initials: JZ
authors.lastname: Wang
authors.forename: Huan
authors.initials: H
authors.lastname: Chen
authors.forename: Kai-yan
authors.initials: KY
authors.lastname: Liu
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Huang
authors.forename: Dao-pei
authors.initials: DP
authors.lastname: Lu
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007938:Leukemia / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D017713:Platelet Transfusion; D012189:Retrospective Studies; D014019:Tissue Donors; D014184:Transplantation, Homologous; D017211:Treatment Failure